Dysregulation of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis

Yuan Chao Xue1,2, Chen Seng Ng1,2, Pinhao Xiang1,2, Huitao Liu1,3, Kevin Zhang1,2, Yasir Mohamud1,2 and Honglin Luo1,2*

1Centre for Heart and Lung Innovation, St. Paul’s Hospital, Vancouver, BC, Canada, 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 3Department of Experimental Medicine, University of British Columbia, Vancouver, BC, Canada

Genetic analyses of patients with amyotrophic lateral sclerosis (ALS) have revealed a strong association between mutations in genes encoding many RNA-binding proteins (RBPs), including TARDBP, FUS, hnRNPA1, hnRNPA2B1, MATR3, ATXN2, TAF15, TIA-1, and EWSR1, and disease onset/progression. RBPs are a group of evolutionally conserved proteins that participate in multiple steps of RNA metabolism, including splicing, polyadenylation, mRNA stability, localization, and translation. Dysregulation of RBPs, as a consequence of gene mutations, impaired nucleocytoplasmic trafficking, posttranslational modification (PTM), aggregation, and sequestration by abnormal RNA foci, has been shown to be involved in neurodegeneration and the development of ALS. While the exact mechanism by which dysregulated RBPs contribute to ALS remains elusive, emerging evidence supports the notion that both a loss of function and/or a gain of toxic function of these ALS-linked RBPs play a significant role in disease pathogenesis through facilitating abnormal protein interaction, causing aberrant RNA metabolism, and by disturbing ribonucleoprotein granule dynamics and phase transition. In this review article, we summarize the current knowledge on the molecular mechanism by which RBPs are dysregulated and the influence of defective RBPs on cellular homeostasis during the development of ALS. The strategies of ongoing clinical trials targeting RBPs and/or relevant processes are also discussed in the present review.

Keywords: aggregation, gene mutations, nucleocytoplasmic transport, RNA-binding proteins, RNA metabolism

INTRODUCTION

Amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease that primarily targets motor neurons, is categorized into two forms, familial (genetically inherited) and sporadic (without apparent family history). Familiar ALS (fALS) is responsible for ~5% to 10% of all ALS cases, whereas sporadic ALS (sALS) is the major form of the disease accounting for 90% to 95% of all cases (Brown and Al-Chalabi, 2017; van Es et al., 2017). Since the first identification of SOD1 as a causative gene for ALS, the list of genetic mutations associated with ALS has grown rapidly. Up to date, more than 30 genes have been recognized as potential causal drivers for ALS (Al-Chalabi et al., 2017). Among them, many encode RNA-binding proteins (RBPs), such as transactivation response DNA-binding protein 43 (TDP-43) and fused in sarcoma/translocated in sarcoma (FUS/TLS).
As key regulators of RNA metabolism, RBPs play a vital role in maintaining the normal function of neuronal systems (Nussbacher et al., 2019). Under physiological conditions, these ALS-linked RBPs are involved in almost all aspects of RNA metabolism, including transcription, alternate splicing, mRNA transport, and stability. Although the exact functions and mechanisms of action of these RBPs are still largely unclear, current evidence suggests a central role for RBPs in the maintenance of neuronal integrity. Defects in RBPs have emerged as a significant contributing factor to the pathogenesis of ALS (Nussbacher et al., 2019). More notably, cytoplasmic mislocalization, aggregation, and fragmentation of RBPs, in particular TDP-43 (termed TDP-43 proteinopathies), have been regarded as a pathological hallmark of ALS or frontotemporal dementia (FTD, a disease sharing many genetic and pathological features with ALS; Neumann et al., 2006; Mackenzie et al., 2010). In this review article, we summarize the current understanding of how RBPs are dysregulated and the role of disrupted RBPs in ALS development. We also highlight the emerging therapeutic intervention by targeting these ALS-implicated RBPs.

MECHANISMS LEADING TO DYSREGULATION OF RBPs IN ALS

As alluded to above, mutations in genes encoding many RBPs are highly associated with ALS. In addition, dysregulation of RBPs as a result of compromised nucleocytoplasmic trafficking, posttranslational modification (PTM), aggregation, and sequestration by abnormal RNAs also contributes significantly to disease pathogenesis. This section will briefly discuss these underlying mechanisms resulting in RBP dysregulation in ALS.

Gene Mutations

Genetic analyses of ALS patients have identified more than 100 ALS-related gene variants, including many genes encoding RBPs, such as TDP-43, FUS, heterogeneous nuclear ribonucleoproteins (hnRNP) A1, hnRNP2/B1, matrin 3 (MATR3), ataxin 2 (ATXN2), TATA-box binding protein–associated factor 15 (TAF15), T-cell–restricted intracellular antigen 1 (TIA-1), and Ewing sarcoma breakpoint region 1 (EWSR1; Al-Chalabi et al., 2018; Ryan et al., 2018). In addition to methylation, via ALS-relevant genetic mutations in RBPs commonly occur in Gly-rich, QGSY-rich, and RGG domains (Kapeli et al., 2017). These gene mutations could lead to loss of function and/or gain of toxic function (will discuss in detail later in this review), contributing to the development of the disease.

Posttranslational Modification

In addition to gene mutations, PTM also serves as an important mechanism for regulating protein structure and function. Aberrant PTM of RBPs is commonly observed in ALS. For example, TDP-43 is extensively posttranslationally modified, including phosphorylation, ubiquitination, acetylation, and sumoylation in both fALS and sALS (Buratti, 2018). Among them, phosphorylation of TDP-43 is the most common PTM of this protein and described as a marker of pathological ALS inclusions (Hasegawa et al., 2008). Several protein kinases have been identified to be responsible for its phosphorylation, including casein kinase (Nonaka et al., 2016), cycle 7-related protein kinase (Liachko et al., 2013), and tau tubulin kinase 1/2 (Liachko et al., 2014). Calcineurin was found to be a phosphatase that regulates TDP-43 phosphorylation (Liachko et al., 2016). Although the exact role of TDP-43 phosphorylation in disease progression remains incompletely understood, clinical data appear to support a function in neurodegeneration (Buratti, 2018).

Another key PTM associated with pathological TDP-43 is the generation of the C-terminal fragments (CTFs), which accumulate in the brains of patients with ALS or FTD and are considered a pathological feature of these diseases (Neumann et al., 2006). Several mechanisms have been proposed for their production, including proteolytic cleavage mediated by cellular proteases such as caspases and calpains, alternative splicing of the TDP-43 gene, and alternate in-frame translation (Buratti, 2018). The CTFs of TDP-43 mislocalize to the cytoplasm due to the removal of nuclear localization signal (NLS) and are prone to form aggregates as compared to the full-length TDP-43 because of the presence of Gly-rich prion-like domain. However, the relative contribution of these CTFs to disease progression remains controversial as transgenic animals expressing CTFs show only subtle motor or behavioral alterations, failing to fully recapitulate those observed in ALS or FTD patients (Berning and Walker, 2019). Methylation is another common type of PTM for RBPs. Methylation often occurs on R residues in RGG motifs of hnRNPs and TEF family of RBPs (i.e., FUS, TAF15, and EWSR1) through the action of protein arginine methyltransferases (Hofweber and Dormann, 2019). Methylation modification is a critical regulator for RBP liquid–liquid phase separation (LLPS) and dynamics of ribonucleoprotein (RNP) granules. Ribonucleoprotein granules, including stress granules (SGs) and processing bodies, are membrane-free, dense cytosolic aggregation of RBPs/RNA and common sites for mRNA storage/degradation (Buchan and Parker, 2009). Disrupted LLPS homeostasis and RNP granule dynamics have been implicated in neurodegeneration. Studies using in vitro systems found that R-methylation on ALS-related RBPs, such as hnRNP2 and FUS, reduces LLPS via inhibiting R-aromatic interaction (Hofweber et al., 2018; Qamar et al., 2018; Ryan et al., 2018). In addition to methylation,
phosphorylation has also been shown to either enhance or suppress RBP phase separation and/or RNP granule dynamics (Hofweber and Dormann, 2019).

**Disrupted Nucleocytoplasmic Trafficking**

RBPs have predominant localizations within the nucleus to perform RNA processing and metabolism. However, many RBPs are abnormally aggregated in the cytoplasm in ALS. As mentioned above, the CTFs of TDP-43 are mainly found in the cytoplasmic aggregates due to the lack of the NLS. In addition, the presence of ALS-related missense mutations within NLS or PTM sites of these RBPs constitutes another mechanism responsible for their cytoplasmic accumulation (Kim and Taylor, 2017). However, gene mutations and fragmentations cannot explain all cases of the observed mislocalization of RBPs.

Emerging evidence proposes impaired nucleocytoplasmic trafficking as a key mechanism for RBP mislocalization in ALS. Although the precise mechanism remains elusive, studies suggest a role for the hexanucleotide repeat expansion mutation in chromosome 9 open reading frame 72 (C9orf72) gene, the most common genetic cause of ALS and FTD (DeJesus-Hernandez et al., 2011; Renton et al., 2011), in such effects. It was found that dipeptide repeats (DPRs) produced from the C9ORF72 expansion mutant accumulate within the nuclear pore complex to disturb its integrity, leading to compromised nucleocytoplasmic transport (Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al., 2015; Shi et al., 2017). Interestingly, a recent study reported that expression of C9ORF72-derived DPR poly-GA (glycine–alanine), but not poly-GR (glycine–proline) and poly-PR (proline–arginine), disturbs nucleocytoplasmic transport (Vanneste et al., 2019), suggesting a DPR-specific role in the regulation of nucleocytoplasmic trafficking. Further investigations revealed that many nucleocytoplasmic transport factors are recruited and sequestrated in the SGs upon stress or treatment with mutant proteins implicated in ALS (Zhang et al., 2018). Importantly, it was found that inhibition of SG formation attenuates the defects in nucleocytoplasmic trafficking and alleviates neurodegeneration in C9orf72-ALS Drosophila models (Zhang et al., 2018).

Recent evidence has also identified a mechanism for the observed cytoplasmic mislocalization of wild-type FUS in ALS (Tyzack et al., 2019). It was found that FUS directly binds to the mRNA of splicing factor proline and glutamine rich (SFPQ). The authors proposed that translocation of SFPQ transcripts to the cytoplasm drives nuclear export of FUS (Tyzack et al., 2019).

**Aggregation and Sequestration by Abnormal RNA Foci**

Protein aggregation is a common event in neurodegenerative diseases, including ALS. Several mechanisms have been recognized to contribute to protein aggregation in ALS, including self-aggregation, altered RNP granule dynamics, sequestration by aberrant RNA foci, and defects in protein quality control system (Conlon and Manley, 2017; Morriss and Cooper, 2017).
Like RNP granules, protein aggregates are formed through LLPS of weak interaction among RBPs and/or RNAs (Hofweber and Dormann, 2019). Many RBPs contain intrinsically disordered low complexity domains (LCDs) that can lead to self-aggregation, especially when abnormally mislocalized, overexpressed, or posttranslationally modified. Interestingly, it was recently reported that factors involved in nuclear import also have a role in phase transition of RBPs (Guo et al., 2018). It was shown that expression of nuclear-import receptors inhibits and reverses aberrant phase separations of RBPs, including TDP-43, FUS, hnRNPA1, hnRNPA2, TAF-15, and EWSR, to restore RBP homeostasis and rescue neurodegeneration caused by ALS-related FUS and hnRNPA1 (Guo et al., 2018). In addition, RBPs can be recruited into RNP granules through interaction with other proteins within the granules. Alternatively, abnormal RNA foci may also lead to RBP aggregations. The GGGGCC repeat RNA of C9ORF72 can fold into G-quadruplexes and/or form stable hairpin-like secondary structures. These RNA structures sequester ALS-associated RBPs, such as TDP-43, and promote protein aggregation. In vivo and in vitro models further demonstrate that enrichment of these abnormal RNA foci can induce misprocessing of RNA transcripts that are commonly regulated by many RBPs (Conlon and Manley, 2017; Morriss and Cooper, 2017). Finally, malfunction of the protein quality control system also has a role in the accumulation of RBP aggregates. Many ALS-related mutations in genes, such as TBK1, p62, OPTN, VCP, and UBNL2, are involved in autophagy and ubiquitin-proteasome degradation (Al-Chalabi et al., 2017). As a consequence of gene mutations and increased proteasomal and lysosomal load due to an excess production of abnormal protein products, the function of the protein quality control system is impaired, resulting in the buildup of RBP aggregates (Cipolat Mis et al., 2016).

**DISRUPTED CELLULAR HOMEOSTASIS CAUSED BY ALS-ASSOCIATED RBPs**

Dysregulation of RBP influences various aspects of the RNA metabolism, resulting in diverse molecular phenotypes, such as disrupted transcription and RNA splicing, abnormal RNA transport, altered mRNA stability, and protein translation. Possible mechanisms involve the loss of function and/or toxic gain of function of these RBPs through aberrant protein interactions, aggregate formation, perturbation of RNP granule dynamics, and phase transition (Figure 2). The following sections will discuss the known/speculated disease mechanisms in genes, including TARDBP, FUS, hnRNPA1, hnRNPA2/B1, TIA1, TAF15, MATR3, and EWSR1.

**TARDBP/TDP-43**

TDP-43 is encoded by the TARDBP gene and belongs to the large family of hnRNPs (Kapeli et al., 2017). TDP-43 participates in multiple steps of RNA processing with its role in splicing being best characterized. For example, research has suggested a role for TDP-43 in cryptic splicing, which is impaired in ALS (Ling et al., 2015). The expression of TDP-43 can be autoregulated at the level of mRNA stability via a negative-feedback loop (Ayala et al., 2011). Under normal conditions, TDP-43 plays a vital role in maintaining the function of the central nervous system (CNS). For example, TDP-43 has been shown to regulate many mRNAs encoding proteins implicated in CNS development, survival, and synaptic transmission and neural plasticity (Polymenidou et al., 2011; Tollervey et al., 2011; Alami et al., 2014; Ling, 2018). Knockout of TDP-43 in mice is embryonic lethal, and conditional or partial loss of TDP-43 in neural cells results in progressive motor neuron degeneration and motor function impairment (Wu et al., 2012; Iguchi et al., 2013; Yang et al., 2014).

TARDBP was first identified as a causative gene for ALS in 2008 (Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008). Since then, more than 50 mutations in TDP-43 have been found in ALS patients, accounting for ~5% of fALS and ~1% of sALS (Taylor et al., 2016). These mutations are predominantly clustered in the Gly-rich domain, an LCD domain critical for protein aggregation and phase transition (Franzmann and Alberti, 2019). Transgenic animals expressing mutant TDP-43 were shown to develop ALS-like pathological and clinical features (Lutz, 2018). Although TDP-43 mutations are rare, TDP-43 proteinopathies, characterized by cytoplasmic mislocalization, aggregation, and cleavage of TDP-43 accompanied by its nuclear clearance, are found in the affected regions of the CNS in up to 97% of all ALS cases, except for those fALS caused by SOD1 or FUS mutations (Neumann et al., 2006; Mackenzie et al., 2010), suggesting a broader involvement for TDP-43 dysregulation in ALS. In addition to the CNS, mislocalization and aggregation of TDP-43 have also been observed in peripheral tissues, such as in the peripheral blood mononuclear cells, in both fALS (De Marco et al., 2017) and sALS (Arosio et al., 2020). The mechanisms for TDP-43 toxicity in ALS are proposed to be both a loss of function (nuclear depletion of TDP-43) and a gain of toxic function, supported by evidence that both knockout and overexpression of wild-type or mutant TDP-43 recapitulate disease phenotypes (Butti and Patten, 2018). Recent studies have established a mechanism by which aberrant RNA splicing caused by mutant TDP-43 or depletion of nuclear TDP-43 contributes to ALS through a loss of function and/or a gain of function (Deshaies et al., 2018; Fratta et al., 2018; Sivakumar et al., 2018). TDP-43 has also been implicated in the DNA damage response, and loss of nuclear TDP-43 causes defects in DNA repair associated with ALS (Mitra et al., 2019). Moreover, dysregulated or mislocalized TDP-43 has been shown to interfere with cellular translational process. For instance, it was discovered that ALS-linked cytoplasmic TDP-43 interacts with receptor for activated C kinase 1 (RACK1), a ribosomal scaffold protein, on polyribosomes, resulting in a global inhibition of protein synthesis (Russo et al., 2017). It was also shown that mutant TDP-43 (A315T) enhances direct binding and translation of several mRNAs, including Dennd4a and Camta1 that are known to be involved in neurodegeneration (Neelagandan et al., 2019).

**Fused in Sarcoma/Translocated in Sarcoma**

Similar to TDP-43, FUS is a DNA/RBP and has primarily nuclear localization, but mislocalizes to the cytoplasm in response to...
Dysregulation of RBPs in ALS. Mutations in RBPs may result in mislocalization within the cells due to disruption in nucleocytoplasmic trafficking, which can lead to the formation of toxic protein aggregates within cytoplasmic inclusions. The accumulation of these aberrant RNA granules enhances the toxicity/pathological effects in mis-regulating normal RNA metabolism and thus leading to neurodegenerative phenotypes such as demyelination, axonal loss, and death of motor neurons.

**FIGURE 2** | Dysregulation of RBPs in ALS. Mutations in RBPs may result in mislocalization within the cells due to disruption in nucleocytoplasmic trafficking, which can lead to the formation of toxic protein aggregates within cytoplasmic inclusions. The accumulation of these aberrant RNA granules enhances the toxicity/pathological effects in mis-regulating normal RNA metabolism and thus leading to neurodegenerative phenotypes such as demyelination, axonal loss, and death of motor neurons.
inclusion/aggregation is uncommon and observed only in almost all ALS cases (Mackenzie et al., 2007), cytoplasmic FUS inclusion/aggregation is uncommon and observed only in FUS-related ALS (Vance et al., 2009) and a very small subset of sALS (Deng et al., 2010). Thus, the contribution of FUS to ALS did not receive as much attention as that of TDP-43. However, a recent study found that cytoplasmic FUS in a diffused form is widely present in ALS, suggesting that it may have a broader role in ALS than previously recognized (Tyzack et al., 2019). This speculation warrants future investigations.

Unlike TDP-43, the function of FUS does not appear to be essential for embryonic development. Global or motor neuron–specific knockout of FUS gene in mice does not cause motor deficits (Sharma et al., 2016), whereas transgenic mice expressing wild-type or mutant FUS were shown to develop severe motor impairments and exhibit progressive neurological symptoms, suggesting a mechanism of toxic gain of function rather than loss of function in FUS-linked ALS pathogenesis (Qiu et al., 2014; Scékic-Zahirovic et al., 2017; López-Erauskin et al., 2018). Although the exact mechanisms of FUS toxicity are still unclear, recent studies began to unravel the involvement of defective RNA binding and splicing, disrupted protein translation, and impaired DNA damage response. ALS–associated mutant FUS has been shown to have altered RNA binding profiles (Hoell et al., 2011), related to the alteration of its subcellular localization (Dormann et al., 2010; Deshpande et al., 2019). Mutant FUS can also cause splicing defects in genes involved in dendritic growth and synaptic functions (Qiu et al., 2014). In addition, ALS–related mutant FUS was found to suppress protein translation at both global and local (axon regions) levels and disrupt the nonsense-mediated decay, both of which are associated with motor neuron pathogenesis seen in human (Kamelgarn et al., 2018; López-Erauskin et al., 2018). Moreover, defects in DNA damage repair were also proposed to be a mechanism underlying FUS–induced ALS pathogenesis. It was reported that DNA damage repair is impaired in human induced pluripotent stem cell (iPSC)–derived motor neurons that carry FUS mutations, leading to the formation of cytoplasmic aggregates and neurodegeneration (Naumann et al., 2018; Wang et al., 2018). Finally, a recent study revealed that activation of antiviral immune response is sufficient to induce the formation and persistence of cytoplasmic FUS–containing aggregates, contributing to onset and progression of FUS proteinopathy (Shelkovichikova et al., 2019).

hnRNPA1 and hnRNPA2/B1
hnRNPA1 and hnRNPA2/B1 are two essential RBPs in the family of hnRNPs. Like other RBPs, hnRNPA1 and hnRNPA2/B1 are typically nuclear localized but accumulate in the cytoplasm under stress conditions (Kapeli et al., 2017). hnRNPA1 and hnRNPA2/B1 share similar functions in the regulation of mRNA maturation, splicing, translation, and stability, but they play a differential role in transcriptional regulation (Kapeli et al., 2017). While knockout of hnRNPA1 is embryonic lethal, and heterozygous mice display defects in muscle development (Liu et al., 2017), knockdown of hnRNPA2/B1 in mice globally disrupts alternative splicing and causes impaired cognitive function (Berson et al., 2012). Genetic analysis identified several ALS-related mutations in both hnRNPA1 and hnRNPA2/B1 (Kim et al., 2013; Couthouis et al., 2014; Liu et al., 2016; Naruse et al., 2018); however, the incidence is low (<1%; Taylor et al., 2016). Although the consequence of these mutations is largely unclear, some evidence suggests that mutations within the LCD could lead to increased cytoplasmic accumulation of hnRNPA1 through misfolding and fibrillation that stabilize the proteins (Kim et al., 2013; Gilpin et al., 2015; Moliex et al., 2015; Liu et al., 2016). It was also reported that altered hnRNPA1 splicing induced by mutant or nuclear depletion of TDP-43 results in the production of an aggregation-prone mutant form of hnRNPA1, contributing to disease progression (Deshaies et al., 2018; Sivakumar et al., 2018). Furthermore, mutations of genes are expected to cause a disruption of protein synthesis as both hnRNPA1 and hnRNPA2/B1 have been implicated in protein translation (Kosturko et al., 2006; Cammas et al., 2007). Finally, iPSC-derived motor neurons expressing ALS-linked hnRNPA2/B1 mutant were shown to have a higher level of cell death and increased stress responses (Martinez et al., 2016).

Others RBPs, Including TIA-1, MATR3, ATXN2, TAF15, and EWSR1
TIA-1 is a critical component of SGs and has multiple functions in RNA metabolism, including mRNA splicing, translational repression, and mRNA silencing. TIA-1 is mainly localized to the nucleus; however, under cellular stress, it translocates to the cytoplasm, where it nucleates SGs and suppresses mRNA translation (Rayman and Kandel, 2017). A number of ALS-related missense mutations in TIA-1 gene have been identified, all of which manifest in the Gly-rich domain (Mackenzie et al., 2017). Mutations of TIA-1 gene were shown to alter LLPS and impair SG disassembly in vitro (Mackenzie et al., 2017). Nonetheless, because of their rare occurrence in patients, the causality between mutations in TIA-1 and the pathogenesis of ALS is still debated (Baradaran-Heravi et al., 2018; van der Spek et al., 2018).

MATR3 is a DNA/RBP that interacts with TDP-43. Similar to other RBPs, MATR3 is involved in different steps of RNA processing, including gene transcription, alternative splicing, mRNA export, and stability (Malik et al., 2018). MATR3 mutations were first reported to be linked to ALS in 2014 (Johnson et al., 2014). Like TIA-1, mutations in MATR3 are rare (<1%) among ALS patients (Taylor et al., 2016). Studies from two recent articles showed that mice expressing mutant MATR3 (S85C or F115C) develop motor dysfunction, accompanied by decreased numbers of motor neurons and activation of microglia and astrocytes in the spinal cord (Mooney et al., 2018; Zhang et al., 2019). Mechanistically, it was found that ALS-linked mutations of this gene decrease mRNA nuclear export and inhibit SG formation (Bohringer et al., 2017). S85C mutation of MATR3 was also shown to disrupt the normal function of MATR3 in mediating phase separation and formation of intranuclear droplets (Gallego-Iradi et al., 2019). Contrary to other ALS-related RBPs, wild-type or mutant MATR3 is
primarily localized to the nucleus even under stress or in ALS postmortem tissues (Johnson et al., 2014; Gallego-Iradi et al., 2015), and the accumulation of MATR3 in the nucleus as opposed to its location in the cytoplasm mediates neurotoxicity (Malik et al., 2018).

ATXN2 is an RBP belonging to the like-Sm (LSm) family and participates in the regulation of RNA metabolism. The ATXN2 gene normally has ~22–23 glutamine (CAG) repeats. Intermediate-size polyQ expansions (24–34 repeats) have been discovered to be significantly associated with the risk of developing ALS (Elden et al., 2010; Sproviero et al., 2017). ATXN2 plays a critical role in regulating TDP-43 and FUS toxicity through direct protein–protein interaction, and reduction of ATXN2 levels has been shown to inhibit TDP-43–mediated neurotoxicity (Elden et al., 2010; Farg et al., 2013; Becker et al., 2017). Both in vitro and knock-in mouse studies demonstrated that polyQ expansion mutants increase the insolubility of ATXN2 and its interacting protein PABPC1, causing neurodegeneration (Damrath et al., 2012).

Mutant forms of both TAF15 and EWSR1 have also been identified in ALS patients (Couthouis et al., 2011, 2012; Ticozzi et al., 2011). Similar to other RBPs, TAF15 and EWSR1 normally reside in the nucleus, but translocate to the cytoplasm upon stress (Neumann et al., 2011; Marko et al., 2012). Expression of disease-related variants of TAF15 and EWSR1 in primary neurons from mouse spinal cord has been reported to cause the formation of cytoplasmic foci. Cytoplasmic TAF15 and EWSR1 aggregates were also detected in some spinal cord neurons of patients with sALS (Couthouis et al., 2011, 2012). Overexpression of wild-type and mutant TAF15 and EWSR1 has been shown to enhance protein aggregation and shorten life span in Drosophila (Couthouis et al., 2011, 2012).

**DEVELOPMENT OF NOVEL THERAPEUTICS BY TARGETING RBPs**

Early studies on ALS therapy have been mostly focused on SOD1. However, SOD1 mutations account for approximately only 20% of FALS and approximately 2% to 3% of all ALS cases (Taylor et al., 2016). Given the recognized importance of RBPs in ALS, RBPs have emerged as critical therapeutic targets for the treatment of ALS.

**Antisense Oligonucleotide**

Antisense oligonucleotides (ASOs) are synthetic single-stranded oligonucleotides that can specifically bind to and accelerate the degradation of the target mRNA via the nuclear endonuclease RNase H. ASO-based gene silencing has been previously tested on mutant SOD1 (mSOD1), and the results are promising (Smith et al., 2006; Miller et al., 2013; McCampbell et al., 2018). It was found that direct delivery of mSOD1-targeted ASOs to the CNS effectively reduces the levels of mSOD1 and significantly delays disease progression and prolongs survival in SOD93A animal models (Smith et al., 2006; McCampbell et al., 2018) and mSOD1-linked ALS patients (Miller et al., 2013). Recently, this technique has been utilized to target ATXN2, a key regulator of TDP-43 neurotoxicity, for degradation (Becker et al., 2017). It was shown that administration of ATXN2-targeted ASOs to the CNS of a mouse model with TDP-43 proteinopathy attenuates TDP-43 pathology and improves motor function (Becker et al., 2017). Moreover, ASO-based strategies have also been successfully used to silence GGGGCC repeat expansion of C9orf72, thereby inhibiting RBPs sequestration by abnormal RNA foci (Donnelly et al., 2013; Sareen et al., 2013).

**Small Molecules**

Small molecules serve as another strategy for ALS treatment by modulating the function and abundance of RBPs. For instance, small molecules that specifically bind to the RRMs (RRM1 and RRM2) of TDP-43 preventing pathogenic interaction of TDP-43 and RNAs led to motor function improvement in vivo (Drosophila, François-Moutal et al., 2019). In addition, inhibition of tankyrase, a poly(ADP-ribose) polymerase, through small molecules was shown to reduce the accumulation of cytoplasmic TDP-43, FUS, or HNRNPA2/B1 aggregates and associated pathologies (McGurk et al., 2018; Fang et al., 2019; Marrone et al., 2019). Various small molecule activators of autophagy, a major cellular pathway for disposing of misfolded protein aggregates and damaged organelles, have also been tested in mutant TDP-43 transgenic mice and in mutant FUS Drosophila models (Wang et al., 2012; Barnada et al., 2014; Marrone et al., 2019). It was shown that application of these autophagy inducers increases the clearance of protein aggregates and improves motor functions and pathologies. Finally, studies using chemical inhibitors to lessen nuclear export of TDP-43 demonstrated a neuroprotective effect (Haines et al., 2015).

**Chaperones**

Molecular chaperones, such as heat shock proteins (HSPs), function to assist proper protein folding and prevent misfolded proteins from aggregation. In addition, chaperones can also guide terminally misfolded proteins to the proteolytic system for degradation (Xiao et al., 2010). In the study of ALS treatment, modified yeast HSP104 was discovered to rescue TDP-43 and FUS proteotoxicity by promoting aggregate dissolution (Jackrel et al., 2014). Moreover, HSPB8, a small HSP, was reported to promote autophagic clearance of misfolded mutant TDP-43 and SOD1, as well as DPRs of C9orf72 (Crippa et al., 2016). Notably, a randomized phase II clinical trial is undertaken to examine the therapeutic value of colchicine, which induces the expression of HSPB8 and several autophagy modulators, in ALS (Mandrioli et al., 2019).

**Antibodies**

Antibody-based therapies have been widely explored for the treatment of neurodegenerative diseases, including ALS. There was a recent study showing beneficial effects of antibodies targeting TDP-43 in ALS (Pozzi et al., 2019). In this study, a single-chain antibody against the RRM1 of TDP-43, a domain involved in protein aggregation and interaction with p65 nuclear factor κB, was generated and delivered into the CNS of TDP-43 mutant transgenic mice through a viral vector. It was found that antibody treatment in these mice significantly reduces neuroinflammation, cognitive impairment, and motor defects (Pozzi et al., 2019).
CONCLUSION

The contribution of dysfunctional RBPs in both fALS and sALS has been greatly appreciated over the last decade since the recognition of TDP-43 as an ALS causal gene and TDP-43 proteinopathy as a hallmark for ALS. The ALS-implicated RBPs share structural and functional similarity. Dysregulated or mutant RBPs have been shown to cause disease phenotype through common protein pathologies, including increased aggregation tendency, cytoplasmic mislocalization, and irregular LLPS and SG dynamics. However, current evidence also points to a distinct function and unique mechanism for individual RBPs in the pathogenesis of ALS. A better understanding of the molecular mechanisms underlying the pathological role of these RBPs in ALS development will lead to a novel avenue for therapeutic intervention for this devastating disease.

REFERENCES

Alami, N. H., Smith, R. B., Carrasco, M. A., Williams, L. A., Winborn, C. S., Han, S. S. W., et al. (2014). Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536–543. doi: 10.1016/j.neuron.2013.12.018

Al-Chalabi, A., van den Berg, L. H., and Veldink, J. (2017). Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat. Rev. Neurol. 13, 96–104. doi: 10.1038/nrneurol.2016.182

Arosio, A., Cristofani, R., Pansarasa, O., Crippa, V., Riva, C., Sirtori, R., et al. (2020). HSC70 expression is reduced in lymphomonocytes of sporadic ALS patients and contributes to TDP-43 accumulation. Amyotroph. Lateral Scler. Frontotemporal. Degener. 21, 51–62. doi: 10.1080/21678421.2019.1672749

Ayala, Y. M., De Conti, L., Avedano-Vázquez, S. E., Dhir, A., Romano, M., D’Ambrogio, A. (2011). TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 30, 277–288. doi: 10.1038/emboj.2010.310

Baradaran-Heravi, Y., Dillen, L., Nguyen, H. P., Van Mosselvede, S., Baets, J., De Jonghe, P., et al. (2018). No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiol. Aging 69, 293.e9–293.e11. doi: 10.1016/j.neurobiolaging.2018.05.005

Barmada, S. J., Serio, A., Arjun, A., Bilican, B., Daub, A., Ando, D. M., et al. (2014). Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 10, 677–685. doi: 10.1038/nchembio.1563

Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367–371. doi: 10.1038/nature22308

Berner, B. A., and Walker, A. K. (2019). The pathology of TDP-43 C-terminal fragments in ALS and FTLD. Front. Neurosci. 13:335. doi: 10.3389/fnins.2019.00335

Berson, A., Barbash, S., Shaltiel, G., Goll, Y., Hanin, G., Greenberg, D. S., et al. (2012). Cholinergic-associated loss of hnRNP-A/B in Alzheimer’s disease impairs cortical splicing and cognitive function in mice. EMBO Mol. Med. 4, 730–742. doi: 10.1002/emmm.201100995

Boehringer, A., Garcia-Mansfield, K., Singh, G., Bakkar, N., Pirrotte, P., and Bowser, R. (2017). ALS associated mutations in Matrin 3 alter protein-protein interactions and impede mRNA nuclear export. Sci. Rep. 7:14529. doi: 10.1038/s41598-017-14924-6

Brown, R. H. Jr., and Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. N. Engl. J. Med. 377:1602. doi: 10.1056/NEJMct1710379

Buchan, J. R., and Parker, R. (2009). Eukaryotic stress granules: the ins and outs of translation. Mol. Cell 36, 932–941. doi: 10.1016/j.molcel.2009.11.020

Buratti, E. (2018). TDP-43 post-translational modifications in health and disease. Expert Opin. Ther. Targets 22, 279–293. doi: 10.1080/14728222.2018.1439923

Butti, Z., and Patten, S. A. (2018). RNA dysregulation in amyotrophic lateral sclerosis. Front. Genet. 9:712. doi: 10.3389/fgene.2018.00712

Cammas, A., Pileur, F., Bonnal, S., Lewis, S. M., Léveque, N., Holcik, M., et al. (2007). Cytoplasmic relocalization of heterogeneous nuclear ribonucleoprotein A1 controls translation initiation of specific mRNAs. Mol. Biol. Cell 18, 5048–5059. doi: 10.1091/mbc.e07-06-0603

Cipolat Mis, M. S., Brajkovic, S., Frattini, E., Di Fonzo, A., and Corti, S. (2016). Autophagy in motor neuron disease: key pathogenetic mechanisms and therapeutic targets. Mol. Cell. Neurosci. 72, 84–90. doi: 10.1016/j.mcn.2016.01.012

Conlon, E. G., and Manley, J. L. (2017). RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev. 31, 1509–1528. doi: 10.1101/gad.304055.117

Couthouis, J., Hart, M. P., Erion, R., King, O. D., Diaz, Z., Nakaya, T., et al. (2012). Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 21, 2899–2911. doi: 10.1093/hmg/dds116

Couthouis, J., Hart, M. P., Shorter, J., Dejesus-Hernandez, M., Erion, R., Oristano, R., et al. (2011). A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. U S A 108, 20881–20890. doi: 10.1073/pnas.1109434108

Couthouis, J., Raphael, A. R., Daneshjou, R., and Gitler, A. D. (2014). Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. PLoS Genet. 10:e1004704. doi: 10.1371/journal.pgen.1004704

Crippa, V., Cicardi, M. E., Ramesh, N., Seguin, S. J., Ganassi, M., Bigi, L., et al. (2016). The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Hum. Mol. Genet. 25, 3908–3924. doi: 10.1093/hmg/ddw232

Damrath, E., Heck, M. V., Gispert, S., Azzizov, M., Nowock, J., Seifried, C., et al. (2012). ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genet. 8:e1002920. doi: 10.1371/journal.pgen.1002920

De Marco, G., Lomartire, A., Calvo, A., Rioso, A., De Luca, E., Mostert, M., et al. (2017). Monocytocytes of patients with amyotrophic lateral sclerosis linked to gene mutations altered TDP-43 subcellular distribution. Neuropathol. Appl. Neurobiol. 43, 133–153. doi: 10.1111/nan.12328

Dejesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in non-SOD1 familial amyotrophic lateral sclerosis. N. Engl. J. Med. 365, 969–981. doi: 10.1056/NEJMoa1100351

Deshaies, J. E., Shkreta, L., Moszczynski, A. J., Sidibé, H., Semmler, S., Fouillen, A., et al. (2014). Targeted RNA-Binding Proteins in ALS

Frontiers in Molecular Neuroscience | www.frontiersin.org 8 May 2020 | Volume 13 | Article 78

AUTHOR CONTRIBUTIONS

All authors contributed to the writing of this article.

FUNDING

This work was supported by the Canadian Institutes of Health Research (PTJ 159546) and the ALS Society of Canada. YM is the recipient of a Doctoral Fellowship from the ALS Canada-Brain Canada. YM and YX are the recipients of UBC Four Year Fellowship. YX is also supported by the UBC ECOSCOPE program. KZ is the recipient of the Faculty of Medicine Summer Student Research program. PX is the recipient of the NSERC Undergraduate Student Research program. CN and HLi are supported by the MITACS Accelerate program.
RNA-Binding Proteins in ALS

Xue et al.

Donnelly, C. J., Zhang, P. W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., et al. (2013). RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. *Neuron* 80, 415–428. doi: 10.1016/j.neuron.2013.10.015

Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, J., Hrusca, A., et al. (2010). ALS-associated fusions in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. *EMBO J.* 29, 2841–2857. doi: 10.1038/emboj.2010.143

Elden, A. C., Kim, H. J., Hart, M. P., Chen-Plotkin, A. S., Johnson, B. S., Fang, X., et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* 466, 1069–1075. doi: 10.1038/nature09320

Fang, M. Y., Markmiller, S., Vu, A. Q., Javaherian, A., Dowdle, W. E., Jolivet, P., et al. (2019). Small-molecule modulation of TDP-43 recruitment to stress granules prevents persistent TDP-43 accumulation in ALS/FTD. *Neuron* 103, 802.e11–819.e11. doi: 10.1016/j.neuron.2019.05.048

Farg, M. A., Soo, K. Y., Warraich, S. T., Dundaramoorthy, V., Blair, I. P., and Atkin, J. D. (2013). Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. *Hum. Mol. Genet.* 22, 7128–7136. doi: 10.1093/hmg/ddt247

François-Moutal, L., Felemban, R., Scott, D. D., Sayegh, M. R., Miranda, V. G., Miranda, V. G., et al. (2015). ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. *EMBO J.* 29, 2841–2857. doi: 10.1038/emboj.2010.143

Hofweber, M., Hutten, S., Bourgeois, B., Spreitzer, E., Niedner-Bolhenz, A., Schifferer, M., et al. (2018). Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. *Cell* 173, 706.e13–719.e13. doi: 10.1016/j.cell.2018.03.004

Iguchi, Y., Katsuno, M., Niwa, J., Takagi, S., Ishigaki, S., Ikenaka, K., et al. (2013). Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. *Brain* 136, 1371–1382. doi: 10.1093/brain/awt029

Jackrel, M. E., DeSantis, M. E., Martinez, B. A., Castellano, L. M., Stewart, R. M., Caldwell, K. A., et al. (2014). Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. *Cell* 156, 170–182. doi: 10.1016/j.cell.2013.11.047

Johnson, J. O., Pioro, E. P., Boehringer, A., Chia, R., Feit, H., Renton, A. E., et al. (2014). Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. *Nat. Neurosci.* 17, 664–666. doi: 10.1038/nn.3888

Jovicic, A., Mertens, J., Boynaems, S., Bogaert, E., Chai, N., Yamada, S. B., et al. (2015). Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. *Nat. Neurosci.* 18, 1226–1229. doi: 10.1038/nn.4085

Kabashi, E., Valdmansis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Vande Velde, C., et al. (2008). TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat. Genet.* 40, 572–574. doi: 10.1038/ng.132

Kamelgarn, M., Chen, J., Kuang, L., Jin, H., Kasarskis, E. J., and Zhu, H. (2018). ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. *Proc. Natl. Acad. Sci. U.S.A* 115, E11904–E11913. doi: 10.1073/pnas.1801431113

Kapeli, K., Martinez, F. J., and Yeo, G. W. (2017). Genetic mutations in RNA-binding proteins and their roles in ALS. *Hum. Genet.* 136, 1193–1214. doi: 10.1007/s00439-017-1836-7

Kim, H. J., and Taylor, J. P. (2017). Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. *Neuron* 96, 285–297. doi: 10.1016/j.neuron.2017.07.029

Kim, H. J., Kim, N. C., Wang, Y. D., Scarborough, E. A., Moore, J., Diaz, Z., et al. (2013). Mutations in prion-like domains in hnrNPA2B1 and hnrNPA1 cause multisystem proteinopathy and ALS. *Nature* 495, 467–473. doi: 10.1038/nature11922

Kosturko, L. D., Maggipinto, M. J., Korza, G., Lee, J. W., Carson, J. H., and Barbarase, E. (2006). Heterogeneous nuclear ribonucleoprotein (hnRNP) E1 binds to hnrNAP2 and inhibits translation of A2 response element mRNAs. *Mol. Biol. Cell* 17, 3521–3533. doi: 10.1091/mbc.e05-10-0946

Kiwatkowski, T. J. Jr., Bosco, D. A., Lederc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* 323, 1205–1208. doi: 10.1126/science.1166066

Lagier-Tourenne, C., Ploimenidou, M., Hutt, K. R., Vu, A. Q., Baughn, M., Huelga, S. C., et al. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. *Nat. Neurosci.* 15, 1488–1497. doi: 10.1038/nn.3230

Liachko, N. F., McMillan, P. J., Guthrie, C. R., Bird, T. D., Leverenz, J. B., and Kramer, B. C. (2013). CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. *Ann. Neurol.* 74, 39–52. doi: 10.1002/ana.23870

Liachko, N. F., McMillan, P. J., Strovas, T. J., Loomis, E., Greenup, L., Murrell, J. R., et al. (2014). The tau tubulin kinesin TTBK1/2 promote accumulation of pathological TDP-43. *PLoS Genet.* 10:e1004803. doi: 10.1371/journal.pgen.1004803

Liachko, N. F., Saxton, A. D., McMillan, P. J., Strovas, T. J., Currey, H. N., Loomis, E., Greenup, L., Murrell, J. R., et al. (2014). The tau tubulin kinesin TTBK1/2 promote accumulation of pathological TDP-43. *PLoS Genet.* 10:e1004803. doi: 10.1371/journal.pgen.1004803
Xue et al. RNA-Binding Proteins in ALS

López-Erauskín, J., Tadokoro, T., Baughn, M. W., Myers, B., McAlonis-Downes, M., Chillon-Marinas, C., et al. (2018). ALS/FTD-linked mutation in FUS suppresses intraxonal protein synthesis and disease without nuclear loss-of-function of FUS. *Neuron* 100, 816.e7–830.e7. doi: 10.1016/j.neuron.2018.09.044

Lutz, C. (1931). Phase models of ALS: Past, present and future. *Brain Res. Rev.* 1693, 1–10. doi: 10.1016/j.brainres.2018.03.024

Mackenzie, I. R., Bigio, E. H., Ince, P. G., Geser, F., Neumann, M., Cairns, N. J., et al. (2007). Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. *Ann. Neurol.* 61, 427–434. doi: 10.1002/ana.21147

Mackenzie, I. R., Nicholson, A. M., Sarkar, M., Messing, J., Purice, M. D., Pottier, C., et al. (2017). TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. *Neuron* 95, 808.e9–816.e9. doi: 10.1016/j.neuron.2017.07.025

Mackenzie, I. R., Rademakers, R., and Neumann, M. (2010). TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. *Lancet Neurol.* 9, 995–1007. doi: 10.1016/S1474-4422(10)70195-2

Malik, A. M., Miguez, R. A., Li, X., Ho, Y. S., Feldman, E. L., and Barmada, S. J. (2018). Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization. *Elife* 7:e35977. doi: 10.7554/elsef.35977

Mandrioli, J., Crippa, V., Cereda, C., Bonetto, V., Zucchi, E., Gessani, A., et al. (2019). Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). *BMJ Open* 9:e028486. doi: 10.1136/bmjopen-2018-028486

Marko, M., Vlassis, A., Guisala, A., and Leichter, M. (2012). Domains involved in TAF15 subcellular localisation: dependence on cell type and ongoing transcription. *Gene* 506, 331–338. doi: 10.1016/j.gene.2012.06.088

Marrone, L., Drexler, H. C. A., Wang, J., Tripathi, P., Distler, T., Heisterkamp, P., et al. (2018). FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. *Acta Neuropathol.* 136, 67–84. doi: 10.1007/s00401-019-01998-x

Martinez, F. J., Pratt, G. A., Van Nostrand, E. L., Batra, R., Huelga, S. C., Marrone, L., Drexler, H. C. A., Wang, J., Tripathi, P., Distler, T., Heisterkamp, P., et al. (2018). Analysis of spinal and muscle pathology in transgenic mice overexpressing wild-type and ALS-linked mutant MATR3. *Nat. Commun.* 9, 1–10. doi: 10.1038/s41467-017-0299-1

Neelagandan, N., Gonnella, G., Dang, S., Janiesch, P. C., Miller, K. K., Kuchler, K., et al. (2019). TDP-43 enhances translation of specific mRNAs linked to neurodegenerative disease. *Nucleic Acids Res.* 47, 341–361. doi: 10.1093/nar/gky792

Neumann, M., Bentmann, E., Dormann, D., Jawaad, A., Dejesus-Hernandez, M., Anzorge, O., et al. (2011). FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. *Brain* 134, 2595–2609. doi: 10.1093/brain/awr201

Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Zhou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 314, 130–133. doi: 10.1126/science.1134108

Nguyen, H. P., Van Broeckhoven, C., and van der Zee, J. (2018). ALS genes in the genome era and their implications for FTD. *Trends Genet.* 34, 404–423. doi: 10.1016/j.tig.2018.03.001

Nonaka, T., Suzuki, G., Tanaka, Y., Kametani, F., Hirai, S., Okado, H., et al. (2016). Phosphorylation of TAR DNA-biding protein of 43 kDa (TDP-43) by truncated casein kinase 18 triggers mislocalization and accumulation of TDP-43. *J. Biol. Chem.* 291, 5473–5483. doi: 10.1074/jbc.m115.695379

Ousseni, B. J., Tabet, R., Yeo, G. W., and Lagier-Tourenne, C. (2019). Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions. *Neurobiol. 102*, 294–320. doi: 10.1016/j.neuron.2019.03.014

Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., et al. (2011). Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat. Neurosci.* 14, 459–468. doi: 10.1038/nn.2779

Poszi, S., Thamimnetty, S. S., Codron, P., Rahimian, R., Plourde, K. V., Soucy, G., et al. (2019). Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. *J. Clin. Invest.* 129, 1581–1595. doi: 10.1172/jci123931

Qamar, S., Wang, G., Randle, S. J., Ruggeri, F. S., Varela, J. A., Lin, J. Q., et al. (2018). FUS phase separation is modulated by a molecular chaperone and methylation of arginine cation–pi interactions. *Cell* 173, 720.e15–734.e15. doi: 10.1016/j.cell.2018.03.056

Qui, H., Lee, S., Shang, Y., Wang, W. Y., Au, K. F., Kamiya, S., et al. (2014). ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. *J. Clin. Investig.* 124, 981–999. doi: 10.1172/jci72723

Rayman, J. B., and Kandel, E. R. (2017). TIA-1 is a functional prion-like protein. *Cold Spring Harb. Perspect. Biol.* 9:a023671. doi: 10.1101/cshperspect.a023671

Reid, J. M., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J. R., et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72, 257–268. doi: 10.1016/j.neuron.2011.09.010

Russo, A., Scardigli, R., La Regina, F., Murray, M. E., Romano, N.,Dickson, D., et al. (2018). Increased cytosolic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. *Hum. Mol. Genet.* 26, 1407–1418. doi: 10.1093/hmg/ddy355

Ryan, V. H., Dignon, G. L., Zerze, G. H., Shaffer, S. E., Elmaleh, M., Connor, T., et al. (2017). Mechanistic view of hnrNPA2-low complexity domain structure, interactions and phase separation altered by mutation and arginine methylation. *Mol. Cell* 69, 465.e7–479.e7. doi: 10.1016/j.molcel.2017.12.022

Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K., Grant, S., Simpson, M., et al. (2013). Targeting RNA foci in iPS-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. *Sci. Transl. Med.* 5:208ra149. doi: 10.1126/scitranslmed.3007529

Séculi-Zahirovic, J., Oussini, H. E., Mersmann, S., Drenner, K., Wagner, M., Sun, Y., et al. (2017). Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. *Acta Neuropathol.* 133, 887–906. doi: 10.1007/s00401-017-1687-9

Sharma, A., Lyashchenko, A. K., Lu, L., Nasrabady, S. E., Elmaleh, M., Mendelsohn, M., et al. (2016). ALS-associated mutant FUS induces selective
motor neuron degeneration through toxic gain of function. Nat. Commun. 7:10465. doi: 10.1038/ncomms10465

Shelkovnikova, T. A., An, H., Shkel, L., Tregoning, J. S., Humphreys, I. R., and Buchman, V. L. (2019). Antiviral immune response as a trigger of FUS proteinopathy in amyotrophic lateral sclerosis. Cell Rep. 29, 4496–4508.e4. doi: 10.1016/j.celrep.2019.11.094

Shi, K. Y., Mori, E., Nizami, Z. F., Lin, Y., Kato, M., Xiang, S., et al. (2017). Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc. Natl. Acad. Sci. U S A 114, E1111–E1117. doi: 10.1073/pnas.1620293114

Sivakumar, P., De Giorgio, F., Ule, A. M., Nieves, J., Nair, R. R., Bentham, M., et al. (2018). TDP-43 mutations increase HNRP A1–7B gain through splicing function. Brain 141:e83. doi: 10.1093/brain/awy260

Smith, R. A., Miller, T. M., Yamanaka, K., Monia, B. P., Condon, T. P., Hung, G., et al. (2008). Antisense oligonucleotide encoded for neurodegenerative disease. J. Clin. Invest. 116, 2290–2296. doi: 10.1172/jci25424

Sproviero, W., Shatunov, A., Stahl, D., Shao, M., van Rheenen, W., Jones, A. R., et al. (2017). ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol. Aging 51, 178.e1–178.e9. doi: 10.1016/j.neurobiolaging.2016.11.010

Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., et al. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668–1672. doi: 10.1126/science.1154584

Taylor, J. P., Brown, R. H., Jr., and Cleveland, D. W. (2016). Decoding ALS: from genes to mechanism. Nature 539, 197–206. doi: 10.1038/nature20413

Ticozzi, N., Vance, C., Leclerc, A. L., Keagly, P., Glass, J. D., McKenna-Yasek, D., et al. (2011). Characterization of the TDP-43 proteins and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 14, 452–458. doi: 10.1038/nn.2778

Tyzack, G. E., Lusier, R., Taha, D. M., Nieves, J., Modic, M., Mitchell, J. S., et al. (2019). Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain 142, 2572–2580. doi: 10.1093/brain/awz217

Van Deerlin, V. M., Sreedharan, J. B., Buchman, V. L. (2019). Antiviral immune response as a trigger of FUS proteinopathy in amyotrophic lateral sclerosis. Lancet 393, 4496.e1–4496.e9. doi: 10.1016/S0140-6736(19)32320-9

Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211. doi: 10.1126/science.1165942

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Xue, Ng, Xiang, Liu, Zhang, Mohamud and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.